Home / People / Hadi Mirzai
Portrait of Hadi Mirzai

Hadi Mirzai

Senior Associate

CMS von Erlach Partners Ltd
Räffelstrasse 26
P.O. Box
8022 Zurich
Languages German, English

Hadi Mirzai's practice covers all aspects of Swiss and EU antitrust law (e.g. horizontal and vertical agreements, dominance abuse, merger control and civil antitrust law). He represents clients in administrative proceedings before the Swiss Competition Commission and courts. Hadi Mirzai has advised clients in a wide range of industries and is particularly experienced in assisting clients in dawn raids as well as in the implementation of compliance programs. In addition to competition law, he focuses on intellectual property, technology law and life sciences. 

Before joining CMS in 2017, Hadi Mirzai has worked in the Construction Division of the Secretariat of the Swiss Competition Commission and gained expertise in competition matters related to the construction sector and public procurement.

more less

Relevant experience

  • Advice to international automotive group in antitrust proceedings before the Swiss Competition Commission regarding horizontal information exchange and price fixing (including amicable settlement with the authority)
  • Representation of financial services provider in investigation regarding an alleged boycott of Apple Pay and other international mobile payment solutions
  • Antitrust advice to leading payment industry company held by competing companies from the financial sector on the implementation of various projects
  • Representation of construction company in the so far largest bid-rigging investigation in Switzerland (canton of Grisons)
  • Advice to ancillary construction trade association on the implementation of industry guidelines
more less

Memberships & Roles

  • Zurich Bar Association (ZAV)
  • Swiss Bar Association (SAV)
  • Antitrust Law Association (Studienvereinigung Kartellrecht e.V.)


more less


more less


  • 2020 Bar admission
  • 2016 Master of Law, University Zurich
  • 2015 Bachelor of Law, University Zurich
more less
10 key as­pects of the re­vised EU com­pet­i­tion law in the field of dis­tri­bu­tion...
The new Ver­tic­al Block Ex­emp­tion Reg­u­la­tion (VBER) and the new ac­com­pa­ny­ing Ver­tic­al Guidelines (VGL) were pub­lished on 10 May 2022. The new VBER will enter in­to force on 1 June 2022 and ap­ply for the next twelve years. The new VBER/VGL in­tro­duce sev


CMS ad­vises the own­er fam­ily on the sale of a ma­jor­ity stake in SCHURTER...
The Swiss in­vestor Capvis, which spe­cial­ises in me­di­um-sized in­vest­ments, ac­quires a ma­jor­ity stake in the Lu­cerne-based SCHURTER Group. The found­ing and pre­vi­ous own­er fam­ily con­tin­ues to hold a stake in the com­pany and is rep­res­en­ted on the board of dir­ect­ors by Thomas Schurter.
CMS ad­vises US tech­no­logy com­pany Bruker on en­ter­ing in­to a cor­por­ate stra­tegic...
Zurich, 4 Janu­ary 2023 Bruker Cor­por­a­tion, a NAS­DAQ-lis­ted US tech com­pany, has entered in­to a part­ner­ship with Swiss firm Biognosys AG to de­liv­er ad­vanced pro­teo­m­ics CRO ser­vices for US bio­pharma and bio­mark­er cus­tom­ers. As part of the part­ner­ship, Bruker has made a ma­jor­ity-own­er­ship in­vest­ment in Biognosys AG. Biognosys is a lead­er in the de­vel­op­ment of pro­teo­m­ics tech­no­lo­gies and solu­tions for phar­ma­ceut­ic­al and bi­otech re­search. The stra­tegic part­ner­ship is ex­pec­ted to cre­ate unique syn­er­gies between Biognosys’ port­fo­lio of pro­teo­m­ics ser­vices, soft­ware and kits, and Bruker’s pi­on­eer­ing tim­sTOF plat­form. As a res­ult of the part­ner­ship, Biognosys plans to open its first ad­vanced pro­teo­m­ics CRO ser­vices labor­at­ory in the US. De­tails of the trans­ac­tion were not dis­closed.An in­ter­na­tion­al CMS team headed by Stefan Brunnsch­weiler and Dr Hendrik Hirsch ad­vised Bruker on all leg­al as­pects of the trans­ac­tion. Bruker has also re­lied on the ex­pert­ise of CMS in the past. Pre­vi­ous work by CMS for Bruker Cor­por­a­tion in­cluded provid­ing leg­al ad­vice on the com­pany’s in­vest­ment in PreO­m­ics.CMS Switzer­land­Stefan Brunnsch­weiler, Lead Part­ner, Zurich, Cor­por­ate / M&AAndrea Relly, Seni­or As­so­ci­ate, Cor­por­ate / M&ASamuel Fe­lix Gang, Seni­or As­so­ci­ate, Cor­por­ate / M&APas­cal Stock­er, Seni­or As­so­ci­ate, Cor­por­ate / M&AAnna Mast, As­so­ci­ate, Cor­por­ate / M&ADr Si­mone Brauch­bar Birkhäuser, Part­ner, In­tel­lec­tu­al Prop­er­ty­Mark Ca­gi­enard, Part­ner, Tax­Sarah Keller, Seni­or As­so­ci­ate, Em­ploy­ment & Pen­sion­sHadi Mirzai, Seni­or As­so­ci­ate, Life Sci­ences and Com­pet­i­tion­Valentina Bal­aj, As­so­ci­ate, Reg­u­lat­ory / Com­pli­anceCMS Ger­manyDr Hendrik Hirsch, Lead Part­ner, Frank­furt/Main, Cor­por­ate/M&ADr Ber­rit Roth-Min­gram, Seni­or As­so­ci­ate, Frank­furt/Main, Cor­por­ate/M&ADr Thomas Hirse, Part­ner, Dus­sel­dorf, In­tel­lec­tu­al Prop­er­tyS­ven Krause, Seni­or As­so­ci­ate, Dus­sel­dorf, In­tel­lec­tu­al Prop­erty
CMS ad­vises Bruker on its in­vest­ment in Nav­ign­ostics
Bruker Cor­por­a­tion, a NAS­DAQ-lis­ted US tech com­pany in the ana­lyt­ic­al in­stru­ment­a­tion sec­tor, in­vests in Nav­ign­ostics. Bruker led the CHF 7.5 mil­lion seed fin­an­cing round, which was also joined by Think.Health Ven­tures, Ven­tura Bio­med In­vestors and Zürch­er Kan­ton­al­bank.Nav­ign­ostics strives to sup­port the se­lec­tion of tar­geted and im­muno-on­co­logy ther­apies tailored to the tu­mour phen­o­type of in­di­vidu­al can­cer pa­tients by us­ing ar­ti­fi­cial in­tel­li­gence driv­en soft­ware com­bined with single-cell re­solved spa­tial pro­teo­m­ic tu­mour data. The fund­ing will strengthen Nav­ign­ostic­s' abil­ity to col­lab­or­ate with clin­ic­al, bi­o­tech­no­logy and phar­ma­ceut­ic­al part­ners and ac­cel­er­ate the de­vel­op­ment of its first dia­gnost­ic product.A team from CMS Switzer­land, led by part­ner Stefan Brunnsch­weiler, ad­vised Bruker on all leg­al mat­ters of the trans­ac­tion. Bruker is a long­stand­ing CMS cli­ent and has been ad­vised by CMS on sev­er­al ac­quis­i­tions and dis­pos­als in the past.CMS Switzer­land­Stefan Brunnsch­weiler, Part­ner, Cor­por­ate / M&APas­cal Stock­er, As­so­ci­ate, Cor­por­ate / M&ADr Si­mone Brauch­bar Birkhäuser, Coun­sel, In­tel­lec­tu­al Prop­er­ty­Hadi Mirzai, As­so­ci­ate, Life Sci­ences and Com­pet­i­tion­Sarah Keller, As­so­ci­ate, Em­ploy­ment 
CMS ad­vises on joint ven­ture between Voigt Hold­ing AG and PHOENIX Pharma...
Zurich, 28 Oc­to­ber 2022The Voigt Group and PHOENIX Pharma Switzer­land have agreed to merge their sub­si­di­ar­ies, each act­ive in phar­ma­ceut­ic­al lo­gist­ics and phar­ma­ceut­ic­al whole­sale sec­tors re­spect­ively, in­to a 50/50 joint ven­ture. The two long-es­tab­lished and fin­an­cially sound com­pan­ies are an ideal fit with com­ple­ment­ary of­fer­ings and com­pet­en­cies in the sup­ply chain.Sub­ject to ap­prov­al by the Swiss Com­pet­i­tion Com­mis­sion, this joint ven­ture will cre­ate a new, com­pet­ent and sus­tain­able play­er in the sup­ply chain of the Swiss health­care mar­ket.A CMS Switzer­land team led by Dr Patrick Som­mer provided com­pre­hens­ive leg­al ad­vice to Voigt Group on this joint ven­ture.CMS Switzer­land: Dr. Patrick Som­mer, Part­ner, Lead, Cor­por­ate / M&A, Com­pet­i­tion & EU­Alain Raemy, Part­ner, Cor­por­ate / M&AM­arquard Christen, Part­ner, Com­pet­i­tion & EU­Dirk Spacek, Part­ner, In­tel­lec­tu­al Prop­er­ty­Dr Si­mone Brauch­bar Birkhäuser, Coun­sel, In­tel­lec­tu­al Prop­er­ty­Hadi Mirzai, As­so­ci­ate, Life Sci­ences, Com­pet­i­tion & EUAl­ex­an­dra Stock­er, As­so­ci­ate, Cor­por­ate / M&AAnna Mast, As­so­ci­ate, Cor­por­ate / M&ADr. Mat­thi­as Kuert, As­so­ci­ate, Bank­ing & Fin­an­ceTho­mas Zweifel, As­so­ci­ate, Real Es­tat­e­Christina Winter, As­so­ci­ate, Em­ploy­ment
Can­nabis law and le­gis­la­tion in Switzer­land
Med­ic­al use Grow­ing, selling and im­port­ing can­nabis for med­ic­al use is al­lowed.However, there is a dis­tinc­tion between can­nabis con­tain­ing at least 1% THC and oth­er can­nabis. Fur­ther­more, un­like THC...
Ad­verse ef­fects of drugs and vac­cines in Switzer­land
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? A...
Spot­light on ap­proaches for com­pre­hens­ive com­pli­ance: New ob­lig­a­tions for...
Be­cause of the trend to­wards a stronger aware­ness of "cor­por­ate so­cial re­spons­ib­il­ity", com­pan­ies both in Switzer­land and abroad are con­fron­ted with grow­ing de­mands for re­spons­ible cor­por­ate gov­ernance...
Spot­light on ap­proaches for com­pre­hens­ive com­pli­ance: New ob­lig­a­tions for...
Be­cause of the trend to­wards a stronger aware­ness of Cor­por­ate So­cial Re­spons­ib­il­ity (CSR), com­pan­ies both in Switzer­land and abroad are con­fron­ted with grow­ing de­mands for re­spons­ible cor­por­ate gov­ernance.The most re­cent ex­ample of leg­al de­vel­op­ments in this area is the in­dir­ect counter-pro­pos­al to the fed­er­al pop­u­lar ini­ti­at­ive "the Re­spons­ible Busi­ness Ini­ti­at­ive – Pro­tect­ing hu­man rights and the en­vir­on­ment" ("Konzern­ver­ant­wor­tungsin­i­ti­at­ive"). With the ex­piry of the ref­er­en­dum dead­line on 5 Au­gust 2021, new due di­li­gence and re­port­ing reg­u­la­tions on non-fin­an­cial mat­ters as well as in areas of con­flict min­er­als and child la­bour are ex­pec­ted to come in­to force in Switzer­land on 1 Janu­ary 2022. In re­cent years, the Gov­ernance, Risk and Com­pli­ance (GRC) ap­proach has been an ef­fi­cient tool for com­pan­ies with com­plex cor­por­ate struc­tures to meet ex­pand­ing reg­u­lat­ory re­quire­ments. By means of a com­pre­hens­ive ap­proach, the areas of Gov­ernance, Risk and Com­pli­ance have been merged and com­pan­ies are well ad­vised to ex­am­ine their com­pli­ance struc­tures crit­ic­ally and, if ne­ces­sary, ad­apt them to the latest de­vel­op­ments.
CMS ad­vised HEB on the di­vest­ment of its stake in SIX lis­ted Cicor to One...
Zurich, 19 Ju­ly 2021 | HEB Swiss In­vest­ment AG, a Zurich-based hold­ing com­pany owned by a Ger­man private in­vestor, has entered in­to an agree­ment to sell its ma­jor stake (29.3 %) in lis­ted Cicor Tech­no­lo­gies...
The Fed­er­al Su­preme Court's judg­ment in the mat­ter "Hors-Liste Medika­mente...
On 21 April 2021, the Fed­er­al Su­preme Court pub­lished a judg­ment against Pf­izer re­gard­ing the sanc­tion or­der of the Com­pet­i­tion Com­mis­sion (COMCO) in the mat­ter Hors-Liste Medika­mente (Pre­isem­p­fehlun­gen)...
Switzer­land in­tro­duces the concept of re­l­at­ive mar­ket power and re­stricts...
On Fri­day, 19 March 2021, the Swiss par­lia­ment ad­op­ted in its fi­nal vote the amended par­lia­ment­ary counter-pro­pos­al to the pop­u­lar ini­ti­at­ive "Stop the high price is­land - for fair prices". This counter-pro­pos­al...
CMS ad­vised DP World on the ac­quis­i­tion of a 44% stake in swis­ster­min­al...
CMS ad­vised DP World on the ac­quis­i­tion of a 44% stake in swis­ster­min­al Hold­ing AG A team un­der the lead of Stefan Brunnsch­weiler has ad­vised DP World, a Dubai-based glob­al port op­er­at­or, on the ac­quis­i­tion...